Literature DB >> 15681450

Genetic analyses of DNA-binding mutants in the catalytic core domain of human immunodeficiency virus type 1 integrase.

Richard Lu1, Ana Limón, Hina Z Ghory, Alan Engelman.   

Abstract

The catalytic core domain (CCD) of human immunodeficiency virus type 1 (HIV-1) integrase (IN) harbors the enzyme active site and binds viral and chromosomal DNA during integration. Thirty-five CCD mutant viruses were constructed, paying particular attention to conserved residues in the Phe(139)-Gln(146) flexible loop and abutting Ser(147)-Val(165) amphipathic alpha helix that were implicated from previous in vitro work as important for DNA binding. Defective viruses were typed as class I mutants (specifically blocked at integration) or pleiotropic class II mutants (additional particle assembly and/or reverse transcription defects). Whereas HIV-1(P145A) and HIV-1(Q146K) grew like the wild type, HIV-1(N144K) and HIV-1(Q148L) were class I mutants, reinforcing previous results that Gln-148 is important for DNA binding and uncovering for the first time an important role for Asn-144 in integration. HIV-1(Q62K), HIV-1(H67E), HIV-1(N120K), and HIV-1(N155K) were also class I mutants, supporting findings that Gln-62 and Asn-120 interact with viral and target DNA, respectively, and suggesting similar integration-specific roles for His-67 and Asn-155. Although results from complementation analyses established that IN functions as a multimer, the interplay between active-site and CCD DNA binding functions was unknown. By using Vpr-IN complementation, we determined that the CCD protomer that catalyzes integration also preferentially binds to viral and target DNA. We additionally characterized E138K as an intramolecular suppressor of Gln-62 mutant virus and IN. The results of these analyses highlight conserved CCD residues that are important for HIV-1 replication and integration and define the relationship between DNA binding and catalysis that occurs during integration in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15681450      PMCID: PMC546573          DOI: 10.1128/JVI.79.4.2493-2505.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  72 in total

1.  Prediction of HIV-1 integrase/viral DNA interactions in the catalytic domain by fast molecular docking.

Authors:  Adeyemi A Adesokan; Victoria A Roberts; Keun Woo Lee; Roberto D Lins; James M Briggs
Journal:  J Med Chem       Date:  2004-02-12       Impact factor: 7.446

2.  Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases.

Authors:  J Kulkosky; K S Jones; R A Katz; J P Mack; A M Skalka
Journal:  Mol Cell Biol       Date:  1992-05       Impact factor: 4.272

3.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

4.  Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases.

Authors:  F Dyda; A B Hickman; T M Jenkins; A Engelman; R Craigie; D R Davies
Journal:  Science       Date:  1994-12-23       Impact factor: 47.728

5.  Metal binding by the D,DX35E motif of human immunodeficiency virus type 1 integrase: selective rescue of Cys substitutions by Mn2+ in vitro.

Authors:  Kui Gao; Steven Wong; Frederic Bushman
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

6.  PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing.

Authors:  F Li; R Goila-Gaur; K Salzwedel; N R Kilgore; M Reddick; C Matallana; A Castillo; D Zoumplis; D E Martin; J M Orenstein; G P Allaway; E O Freed; C T Wild
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-22       Impact factor: 11.205

7.  Unintegrated lentivirus DNA persistence and accessibility to expression in nondividing cells: analysis with class I integrase mutants.

Authors:  Dyana T Saenz; Nils Loewen; Mary Peretz; Todd Whitwam; Román Barraza; Kyle G Howell; Jonathan M Holmes; Margaret Good; Eric M Poeschla
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

8.  Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression.

Authors:  S Y Kim; R Byrn; J Groopman; D Baltimore
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

9.  Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication.

Authors:  A Engelman; G Englund; J M Orenstein; M A Martin; R Craigie
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

10.  Simian virus 40-based replication of catalytically inactive human immunodeficiency virus type 1 integrase mutants in nonpermissive T cells and monocyte-derived macrophages.

Authors:  Richard Lu; Noriko Nakajima; Wolfgang Hofmann; Monsef Benkirane; Kuan-Teh Jeang; Joseph Sodroski; Alan Engelman; Kuan Teh-Jeang
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

View more
  43 in total

1.  A new functional role of HIV-1 integrase during uncoating of the viral core.

Authors:  Marisa S Briones; Samson A Chow
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

2.  Correlation of recombinant integrase activity and functional preintegration complex formation during acute infection by replication-defective integrase mutant human immunodeficiency virus.

Authors:  Xiang Li; Yasuhiro Koh; Alan Engelman
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

3.  Revealing domain structure through linker-scanning analysis of the murine leukemia virus (MuLV) RNase H and MuLV and human immunodeficiency virus type 1 integrase proteins.

Authors:  Jennifer Puglia; Tan Wang; Christine Smith-Snyder; Marie Cote; Michael Scher; Joelle N Pelletier; Sinu John; Colleen B Jonsson; Monica J Roth
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir.

Authors:  Mathieu Métifiot; Kasthuraiah Maddali; Alena Naumova; Xuemin Zhang; Christophe Marchand; Yves Pommier
Journal:  Biochemistry       Date:  2010-05-04       Impact factor: 3.162

5.  Interaction between Reverse Transcriptase and Integrase Is Required for Reverse Transcription during HIV-1 Replication.

Authors:  Shewit S Tekeste; Thomas A Wilkinson; Ethan M Weiner; Xiaowen Xu; Jennifer T Miller; Stuart F J Le Grice; Robert T Clubb; Samson A Chow
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

6.  Division of labor within human immunodeficiency virus integrase complexes: determinants of catalysis and target DNA capture.

Authors:  Tracy L Diamond; Frederic D Bushman
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

7.  Subunit-specific protein footprinting reveals significant structural rearrangements and a role for N-terminal Lys-14 of HIV-1 Integrase during viral DNA binding.

Authors:  Zhuojun Zhao; Christopher J McKee; Jacques J Kessl; Webster L Santos; Janet E Daigle; Alan Engelman; Gregory Verdine; Mamuka Kvaratskhelia
Journal:  J Biol Chem       Date:  2007-12-19       Impact factor: 5.157

8.  Molecular mechanisms by which human immunodeficiency virus type 1 integrase stimulates the early steps of reverse transcription.

Authors:  Charles W Dobard; Marisa S Briones; Samson A Chow
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

9.  The role of lysine 186 in HIV-1 integrase multimerization.

Authors:  Lionel Berthoux; Sarah Sebastian; Mark A Muesing; Jeremy Luban
Journal:  Virology       Date:  2007-03-29       Impact factor: 3.616

10.  Transgene expression in the mouse cerebellar Purkinje cells with a minimal level of integration using long terminal repeat-modified lentiviral vectors.

Authors:  Kiyohiko Takayama; Takashi Torashima
Journal:  J Neurovirol       Date:  2009-09       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.